Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 16/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15414077 | 0.80 | POLB (0.49) | PDK1EPHA2EPHB4 | |
| SCHEMBL554078 | 0.80 | PDK1 (0.44) | PDK1EPHA2HRH3 | |
| SCHEMBL21682722 | 0.79 | MEN1 (0.51) | PDK1 | |
| SCHEMBL14871716 | 0.79 | PDK1 (0.48) | PDK1HRH3 | |
| SCHEMBL15797983 | 0.79 | PDK1 (0.48) | PDK1HRH3 | |
| SCHEMBL23089305 | 0.79 | PDK1 (0.65) | PDK1HRH3 | |
| SCHEMBL22320561 | 0.79 | PDK1 (0.41) | PDK1EPHA2KDREPHB4HRH3 | |
| SCHEMBL22320559 | 0.79 | PDK1 (0.41) | PDK1EPHA2KDREPHB4HRH3 | |
| SCHEMBL2522781 | 0.78 | PDK1 (0.45) | PDK1EPHA2KDREPHB4 | |
| SCHEMBL16096341 | 0.77 | RBP4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872514-B1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20160108050-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-21 | — | — | US | disclosed |
| US-9273057-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150210697-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-30 | — | — | US | disclosed |
| EP-2872514-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014011974-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210697-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | PDK1 333/4885EPHA2 2914/4885KDR 1011/4885 |
| US-20160108050-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | PDK1 333/4885EPHA2 2914/4885KDR 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.